Gross Margin % is calculated as gross profit divided by its revenue. Azitra's Gross Profit for the
three
months ended in Dec. 2024 was $-0.59 Mil. Azitra's Revenue for the
three
months ended in Dec. 2024 was $-0.59 Mil. Therefore, Azitra's Gross Margin % for the quarter that ended in Dec. 2024 was 0.00%.
If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.
The historical rank and industry rank for Azitra's Gross Margin % or its related term are showing as below:
AZTR's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.72 * Ranked among companies with meaningful Gross Margin % only.
Azitra had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Azitra was 0.00% per year.
Azitra Gross Margin % Historical Data
The historical data trend for Azitra's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Azitra's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Azitra's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Azitra's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Azitra's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Azitra (AMEX:AZTR) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Azitra had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Azitra Gross Margin % Related Terms
Thank you for viewing the detailed overview of Azitra's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AZTR has been successfully added to your 